The kallikrein-kinin system in diabetic nephropathy

Kidney International

Volumn 81, Issue 8, 2012, Pages 733-744

  Tomita, Hirofumi ^a   Sanford, Ryan B ^a   Smithies, Oliver ^a   Kakoki, Masao ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; bradykinin; diabetic nephropathy; nitric oxide; oxidative stress

Indexed keywords

ARGININE; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CALCIUM ION; CAPTOPRIL; CICAPROST; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; IRBESARTAN; KALLIKREIN; KININ; LISINOPRIL; LOSARTAN; NEPHRIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ALBUMINURIA; ALLELE; ANGIOTENSIN I CONVERTING ENZYME GENE; BRADYKININ B2 RECEPTOR GENE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; GENE; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KALLIKREIN KININ SYSTEM; KIDNEY INJURY; MICROALBUMINURIA; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEINURIA; RECEPTOR DOWN REGULATION; RECEPTOR GENE; RECEPTOR UPREGULATION; RENAL PROTECTION; REVIEW; RISK REDUCTION; TREATMENT RESPONSE;

EID: 84859428917     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.499     Document Type: Review

References (150)

1. Skidgel RA, Engelbrecht S, Johnson AR et al. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984; 5: 769-776. (Pubitemid 14058557)
2. Kakoki M, Smithies O. The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 2009; 75: 1019-1030.
3. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993; 268: 9496-9503. (Pubitemid 23146003)
4. Ishida H, Scicli AG, Carretero OA. Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension 1989; 14: 322-327. (Pubitemid 19220009)
5. Smithies O, Kim HS, Takahashi N et al. Importance of quantitative genetic variations in the etiology of hypertension. Kidney Int 2000; 58: 2265-2280.
6. Takahashi N, Hagaman JR, Kim HS et al. Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology 2003; 144: 2184-2190. (Pubitemid 36629864)
7. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-449. (Pubitemid 24102039)
8. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346. (Pubitemid 20370444)
9. Lachurie ML, Azizi M, Guyene TT et al. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995; 91: 2933-2942.
10. Marre M, Bernadet P, Gallois Y et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43: 384-388. (Pubitemid 24064244)
11. Tarnow L, Gluud C, Parving HH. Diabetic nephropathy and the insertion/ deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998; 13: 1125-1130. (Pubitemid 28227184)
12. Stephens JW, Dhamrait SS, Acharya J et al. A common variant in the ACE gene is associated with peripheral neuropathy in women with type 2 diabetes mellitus. J Diabet Compl 2006; 20: 317-321. (Pubitemid 44292531)
13. Rabensteiner D, Abrahamian H, Irsigler K et al. ACE gene polymorphism and proliferative retinopathy in type 1 diabetes: results of a case-control study. Diabetes Care 1999; 22: 1530-1535. (Pubitemid 29418251)
14. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
15. Doi Y, Yoshinari M, Yoshizumi H et al. Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis 1997; 132: 145-150. (Pubitemid 27311005)
16. Murphey LJ, Gainer JV, Vaughan DE et al. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000; 102: 829-832.
17. Almeida SS, Barros CC, Moraes MR et al. Plasma kallikrein and angiotensin I-converting enzyme N- and C-terminal domain activities are modulated by the insertion/deletion polymorphism. Neuropeptides 2010; 44: 139-143.
18. Krege JH, Kim HS, Moyer JS et al. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 1997; 29: 150-157. (Pubitemid 27074036)
19. Huang W, Gallois Y, Bouby N et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98: 13330-13334. (Pubitemid 33051362)
20. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462. (Pubitemid 23335891)
21. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951. (Pubitemid 39447135)
22. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330.
23. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
24. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
25. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-281. (Pubitemid 36992197)
26. Navar LG. The intrarenal renin-angiotensin system in hypertension. Kidney Int 2004; 65: 1522-1532. (Pubitemid 38407000)
27. Campbell DJ, Kelly DJ, Wilkinson-Berka JL et al. Increased bradykinin and 'normal' angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int 1999; 56: 211-221. (Pubitemid 29300537)
28. Hollenberg NK, Price DA, Fisher ND et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003; 63: 172-178. (Pubitemid 35463918)
29. Kobori H, Nangaku M, Navar LG et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287. (Pubitemid 47481436)
30. Duncan AM, Kladis A, Jennings GL et al. Kinins in humans. Am J Physiol Regul Integr Comp Physiol 2000; 278: R897-R904. (Pubitemid 30215202)
31. Zeitz CJ, Campbell DJ, Horowitz JD. Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans. Hypertension 2003; 41: 482-487. (Pubitemid 36314620)
32. Tschope C, Seidl U, Reinecke A et al. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. Int Immunopharmacol 2003; 3: 335-344. (Pubitemid 36293962)
33. Allard J, Buleon M, Cellier E et al. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007; 293: F1083-F1092. (Pubitemid 47583940)
34. Schafer S, Schmidts HL, Bleich M et al. Nephroprotection in zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol 2004; 143: 27-32. (Pubitemid 39280021)
35. Buleon M, Allard J, Jaafar A et al. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 2008; 294: F1249-F1256.
36. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111: 315-320. (Pubitemid 40165338)
37. Liu YH, Yang XP, Sharov VG et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-1935. (Pubitemid 27175940)
38. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100: 264-269. (Pubitemid 27349072)
39. Batenburg WW, Garrelds IM, Bernasconi CC et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004; 109: 2296-2301. (Pubitemid 38656868)
40. Hornig B, Kohler C, Schlink D et al. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor- dependent mechanism. Hypertension 2003; 41: 1092-1095. (Pubitemid 36548608)
41. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935. (Pubitemid 29536342)
42. Ruggenenti P, Bettinaglio P, Pinares F et al. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 2008; 3: 1511-1525.
43. Penno G, Chaturvedi N, Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: Findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998; 47: 1507-1511. (Pubitemid 28396957)
44. Jacobsen P, Rossing K, Rossing P et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998; 53: 1002-1006. (Pubitemid 28155676)
45. Jacobsen P, Tarnow L, Carstensen B et al. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 2003; 14: 2843-2850. (Pubitemid 37305647)
46. So WY, Ma RC, Ozaki R et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients: interaction with ace insertion/ deletion polymorphism. Kidney Int 2006; 69: 1438-1443.
47. Parving HH, de Zeeuw D, Cooper ME et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008; 19: 771-779.
48. Regoli D, Rizzi A, Perron SI et al. Classification of kinin receptors. Biol Chem 2001; 382: 31-35.
49. Leeb-Lundberg LM, Marceau F, Muller-Esterl W et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77. (Pubitemid 40283969)
50. Kakoki M, McGarrah RW, Kim HS et al. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2007; 104: 7576-7581. (Pubitemid 47185948)
51. Ni A, Chao L, Chao J. Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem 1998; 273: 2784-2791. (Pubitemid 28133925)
52. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998; 50: 357-386.
53. Spillmann F, Altmann C, Scheeler M et al. Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. Int Immunopharmacol 2002; 2: 1823-1832. (Pubitemid 35373923)
54. Schremmer-Danninger E, Offner A, Siebeck M et al. B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem Biophys Res Commun 1998; 243: 246-252. (Pubitemid 28414222)
55. Morand-Contant M, Anand-Srivastava MB, Couture R. Kinin B1 receptor upregulation by angiotensin II and endothelin-1 in rat vascular smooth muscle cells: receptors and mechanisms. Am J Physiol Heart Circ Physiol 2010; 299: H1625-H1632.
56. Larrivee JF, Bachvarov DR, Houle F et al. Role of the mitogen-activated protein kinases in the expression of the kinin B1 receptors induced by tissue injury. J Immunol 1998; 160: 1419-1426. (Pubitemid 28093443)
57. Schanstra JP, Bataille E, Marin Castano ME et al. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest 1998; 101: 2080-2091. (Pubitemid 28244092)
58. Bachvarov DR, Hess JF, Menke JG et al. Structure and genomic organization of the human B1 receptor gene for kinins (BDKRB1). Genomics 1996; 33: 374-381. (Pubitemid 26159854)
59. Kakoki M, Takahashi N, Jennette JC et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004; 101: 13302-13305. (Pubitemid 39209660)
60. Duka I, Kintsurashvili E, Gavras I et al. Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension. Circ Res 2001; 88: 275-281. (Pubitemid 32173750)
61. Westermann D, Walther T, Savvatis K et al. Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 2009; 58: 1373-1381.
62. Seguin T, Buleon M, Destrube M et al. Hemodynamic and renal involvement of B1 and B2 kinin receptors during the acute phase of endotoxin shock in mice. Int Immunopharmacol 2008; 8: 217-221.
63. Pietrovski EF, Otuki MF, Regoli D et al. The non-peptide kinin receptor antagonists FR 173657 and SSR 240612: preclinical evidence for the treatment of skin inflammation. Regul Pept 2009; 152: 67-72.
64. Bodin S, Chollet C, Goncalves-Mendes N et al. Kallikrein protects against microalbuminuria in experimental type 1 diabetes. Kidney Int 2009; 76: 395-403.
65. Christopher J, Jaffa AA. Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol 2002; 2: 1771-1779. (Pubitemid 35373920)
66. Mage M, Pecher C, Neau E et al. Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Can J Physiol Pharmacol 2002; 80: 328-333. (Pubitemid 34451249)
67. Yoshioka M, Kayo T, Ikeda T et al. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997; 46: 887-894. (Pubitemid 27188269)
68. Rodriguez AI, Pereira-Flores K, Hernandez-Salinas R et al. High glucose increases B1-kinin receptor expression and signaling in endothelial cells. Biochem Biophys Res Commun 2006; 345: 652-659. (Pubitemid 43776984)
69. Christopher J, Velarde V, Zhang D et al. Regulation of B(2)-kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2001; 280: H1537-H1546.
70. Campbell DJ, Kladis A, Zhang Y et al. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 2010; 53: 779-785.
71. Kakoki M, Kizer CM, Yi X et al. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 2006; 116: 1302-1309.
72. Tan Y, Keum JS, Wang B et al. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 2007; 293: F1026-F1035. (Pubitemid 47583934)
73. Brosius III FC, Alpers CE, Bottinger EP et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2503-2512.
74. Lagneux C, Bader M, Pesquero JB et al. Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2002; 2: 815-822. (Pubitemid 34603126)
75. Cayla C, Todiras M, Iliescu R et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 2007; 21: 1689-1698. (Pubitemid 46855614)
76. Kakoki M, Sullivan KA, Backus C et al. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci USA 2010; 107: 10190-10195.
77. Yuan G, Deng J, Wang T et al. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 50-monophosphate-activated protein kinase signaling pathways. Endocrinology 2007; 148: 2016-2026. (Pubitemid 46997049)
78. Braun A, Kammerer S, Maier E et al. Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology 1996; 33: 32-35.
79. Lung CC, Chan EK, Zuraw BL. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol 1997; 99: 134-146. (Pubitemid 27074907)
80. Maltais I, Bachvarova M, Maheux P et al. Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/ creatinine values in diabetic patients. Can J Physiol Pharmacol 2002; 80: 323-327. (Pubitemid 34451248)
81. Dhamrait SS, Payne JR, Li P et al. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J 2003; 24: 1672-1680. (Pubitemid 37174908)
82. Van Guilder GP, Pretorius M, Luther JM et al. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 2008; 51: 454-459. (Pubitemid 351156432)
83. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-1373. (Pubitemid 36519197)
84. Qian Y, Feldman E, Pennathur S et al. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008; 57: 1439-1445.
85. Bascands JL, Pecher C, Rouaud S et al. Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am J Physiol 1993; 264: F548-F556. (Pubitemid 23102772)
86. Bascands JL, Pecher C, Bompart G et al. Bradykinin-induced in vitro contraction of rat mesangial cells via a B2 receptor type. Am J Physiol 1994; 267: F871-F878.
87. Duchene J, Schanstra JP, Pecher C et al. A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation. J Biol Chem 2002; 277: 40375-40383. (Pubitemid 35215611)
88. Alric C, Pecher C, Cellier E et al. Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int 2002; 62: 412-421. (Pubitemid 34779752)
89. Schanstra JP, Neau E, Drogoz P et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371-379. (Pubitemid 34847969)
90. Okada H, Watanabe Y, Kikuta T et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol 2004; 15: 2404-2413. (Pubitemid 39159340)
91. Suzuki D, Miyata T, Nangaku M et al. Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. J Am Soc Nephrol 1999; 10: 2606-2613.
92. Aaltonen P, Luimula P, Astrom E et al. Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001; 81: 1185-1190. (Pubitemid 32911967)
93. Klein J, Gonzalez J, Duchene J et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 2009; 23: 134-142.
94. Wang PH, Cenedeze MA, Campanholle G et al. Deletion of bradykinin B1 receptor reduces renal fibrosis. Int Immunopharmacol 2009; 9: 653-657.
95. Pereira RL, Buscariollo BN, Correa-Costa M et al. Bradykinin receptor 1 activation exacerbates experimental focal and segmental glomerulosclerosis. Kidney Int 2011; 79: 1217-1227.
96. Klein J, Gonzalez J, Decramer S et al. Blockade of the kinin B1 receptor ameliorates glomerulonephritis. J Am Soc Nephrol 2010; 21: 1157-1164.
97. Riser BL, Denichilo M, Cortes P et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38. (Pubitemid 30020423)
98. Yamamoto T, Nakamura T, Noble NA et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818. (Pubitemid 23069947)
99. Minchenko AG, Stevens MJ, White L et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003; 17: 1514-1516.
100. Sanderson N, Factor V, Nagy P et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92: 2572-2576.
101. Yokoi H, Mukoyama M, Mori K et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 2008; 73: 446-455. (Pubitemid 351186294)
102. Hocher B, Thone-Reineke C, Rohmeiss P et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380-1389. (Pubitemid 27142776)
103. Chao J, Li HJ, Yao YY et al. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension 2007; 49: 490-497.
104. Hartman JC, Wall TM, Hullinger TG et al. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993; 21: 996-1003. (Pubitemid 23160691)
105. Liu YH, Yang XP, Sharov VG et al. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996; 27: 7-13. (Pubitemid 26017674)
106. Yang XP, Liu YH, Mehta D et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 2001; 88: 1072-1079. (Pubitemid 34137121)
107. Emanueli C, Maestri R, Corradi D et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 1999; 100: 2359-2365.
108. Maestri R, Milia AF, Salis MB et al. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 2003; 41: 1151-1155. (Pubitemid 36548618)
109. Wende AR, Soto J, Olsen CD et al. Loss of bradykinin signaling does not accelerate the development of cardiac dysfunction in type 1 diabetic Akita mice. Endocrinology 2010; 151: 3536-3542.
110. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
111. Ignarro LJ, Cirino G, Casini A et al. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999; 34: 879-886.
112. Stuehr DJ. Mammalian nitric oxide synthases. Biochim Biophys Acta 1999; 1411: 217-230. (Pubitemid 29221951)
113. Venema RC, Sayegh HS, Kent JD et al. Identification, characterization, and comparison of the calmodulin-binding domains of the endothelial and inducible nitric oxide synthases. J Biol Chem 1996; 271: 6435-6440.
114. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999; 43: 521-531. (Pubitemid 29369251)
115. Kuhr F, Lowry J, Zhang Y et al. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010; 44: 145-154.
116. Couture R, Girolami JP. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 2004; 500: 467-485. (Pubitemid 39304028)
117. Drummond GR, Cocks TM. Endothelium-dependent relaxations mediated by inducible B1 and constitutive B2 kinin receptors in the bovine isolated coronary artery. Br J Pharmacol 1995; 116: 2473-2481.
118. Sangsree S, Brovkovych V, Minshall RD et al. Kininase I-type carboxypeptidases enhance nitric oxide production in endothelial cells by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ Physiol 2003; 284: H1959-H1968. (Pubitemid 36622405)
119. Ignjatovic T, Stanisavljevic S, Brovkovych V et al. Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol 2004; 66: 1310-1316. (Pubitemid 39411071)
120. Savard M, Barbaz D, Belanger S et al. Expression of endogenous nuclear bradykinin B2 receptors mediating signaling in immediate early gene activation. J Cell Physiol 2008; 216: 234-244. (Pubitemid 351813114)
121. Schanstra JP, Duchene J, Praddaude F et al. Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 2003; 284: H1904-H1908. (Pubitemid 36622398)
122. Zanchi A, Moczulski DK, Hanna LS et al. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000; 57: 405-413. (Pubitemid 30430632)
123. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000; 49: 500-503. (Pubitemid 30131798)
124. Reyes AA, Karl IE, Kissane J et al. L-Arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol 1993; 4: 1039-1045.
125. Kamijo H, Higuchi M, Hora K. Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Nephron Physiol 2006; 104: p12-p22.
126. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669. (Pubitemid 44484656)
127. Mohan S, Reddick RL, Musi N et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 2008; 88: 515-528. (Pubitemid 351581457)
128. Nakagawa T, Sato W, Glushakova O et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18: 539-550. (Pubitemid 46193319)
129. Wang CH, Li F, Hiller S et al. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci USA 2011; 108: 2070-2075.
130. Kakoki M, Hirata Y, Hayakawa H et al. Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 1999; 99: 1242-1248. (Pubitemid 29120098)
131. Choi KC, Lee SC, Kim SW et al. Role of nitric oxide in the pathogenesis of diabetic nephropathy in streptozotocin-induced diabetic rats. Korean J Intern Med 1999; 14: 32-41.
132. Trachtman H, Futterweit S, Pine E et al. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr Nephrol 2002; 17: 20-29. (Pubitemid 41490200)
133. Hakim FA, Pflueger A. Role of oxidative stress in diabetic kidney disease. Med Sci Monit 2010; 16: RA37-RA48.
134. Huang C, Kim Y, Caramori ML et al. Diabetic nephropathy is associated with gene expression levels of oxidative phosphorylation and related pathways. Diabetes 2006; 55: 1826-1831. (Pubitemid 44324139)
135. Kanwar YS, Wada J, Sun L et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233: 4-11.
136. Ueno Y, Horio F, Uchida K et al. Increase in oxidative stress in kidneys of diabetic Akita mice. Biosci Biotechnol Biochem 2002; 66: 869-872. (Pubitemid 39251354)
137. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625. (Pubitemid 40770750)
138. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-1070.
139. 2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001; 50: 2114-2125.
140. DeRubertis FR, Craven PA, Melhem MF et al. Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 2004; 53: 762-768. (Pubitemid 38270647)
141. +/-AkitaJ mice by the mitochondria-targeted therapy mitoQ. Biochem J 2010; 432: 9-19.
142. Cleeter MW, Cooper JM, Darley-Usmar VM et al. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett 1994; 345: 50-54. (Pubitemid 24154664)
143. Brown GC, Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett 1994; 356: 295-298. (Pubitemid 24376992)
144. Schweizer M, Richter C. Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. Biochem Biophys Res Commun 1994; 204: 169-175. (Pubitemid 24335277)
145. Lee I, Salomon AR, Ficarro S et al. cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity. J Biol Chem 2005; 280: 6094-6100. (Pubitemid 40280094)
146. Piccoli C, Scacco S, Bellomo F et al. cAMP controls oxygen metabolism in mammalian cells. FEBS Lett 2006; 580: 4539-4543. (Pubitemid 44118245)
147. Oeseburg H, Iusuf D, van der Harst P et al. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension 2009; 53: 417-422.
148. Zhang JJ, Bledsoe G, Kato K et al. Tissue kallikrein attenuates
149. Villa E, Rabano A, Ruilope LM et al. Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997; 10: 202-208. (Pubitemid 27084632)
150. Mikrut K, Paluszak J, Kozlik J et al. The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia. Diabetes Res Clin Pract 2001; 51: 79-85. (Pubitemid 32140860)